GlobeNewswire

Chartbeat Announces the 100 Most Engaging Stories of 2017

Dela

The Atlantic's "My Family's Slave" is the most engaging article of the year

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Chartbeat, the leading content intelligence platform for publishers, today announces the 100 Most Engaging Stories of 2017, the articles that were read most this year based on highest Engaged Time. Selected out of over 39 million stories on over 50,000 media sites around the world, the top 100 serve as a snapshot of the year's major events and highlight the themes that resonated most with readers.

While "Trump" was by far the number-one entity referenced in news stories according to Chartbeat's global dataset, reader attention was consumed by more than just politics. Authentic, personal accounts of human struggle from The Atlantic and ESPN, breaking news about the Weinstein allegations from The New York Times and political coverage of Trump's White House from many including The Washington Post topped the list, as well as terror, disaster and health articles from companies including the BBC, CNN and many more.

"Each year the Most Engaging Stories list affirms that readers want compelling journalism and storytelling that reports, educates, informs, and helps them make sense of the world," said John Saroff, CEO of Chartbeat. 

The Atlantic's "My Family's Slave" earned the top spot on the list. The piece, written by the late Alex Tizon, gives a truthful, humble account of his life growing up with his caretaker Lola, simultaneously a beloved mother figure and "slave" in his family home. Collecting almost 58 million minutes of Engaged Time - triple of any other article on the list - the story garnered widespread global readership and debate, and is a marquee example of the human-centered stories making their presence strongly known on this year's list.

"People value story, great writing and honest emotion," said The Atlantic's editor-in-chief, Jeffrey Goldberg. "When we published Alex Tizon's piece, we were at the beginning of the Trump presidency, and Trump was seemingly the only thing on everyone's minds. I had no idea that a tragic, very personal story by an esteemed but not particularly well-known writer would connect in such a dramatic way. But we learned that the marketplace still rewards quality."

The top ten most engaging stories that follow The Atlantic's "My Family's Slave" are:

  1. ESPN:  "I Just Wanted To Survive" by Tisha Thompson and Andy Lockett
  2. The New York Times:  Multiple Weapons Found in Las Vegas Gunman's Hotel Room
  3. CNN:  Something went 'incredibly wrong' with Las Vegas gunman, brother says by Emanuella Grinberg
  4. The Atlantic:  Have Smartphones Destroyed a Generation? Jean M. Twenge
  5. CNNWeapons cache found at Las Vegas shooter's home By Holly Yan, Philip Victor and Darran Simon
  6. The New York Times:  Harvey Weinstein Paid Off Sexual Harassment Accusers for Decades Jodi Kantor and Megan Twohey
  7. The New York Times:  You May Want to Marry My Husband by Amy Krouse Rosenthal
  8. The New York Times:  Pictures From Women's Marches on Every Continent
  9. The New York Times:  The Lost Children of Tuam by Dan Barry

For more information on the 100 Most Engaging Stories of 2017, please visit 2017.chartbeat.com or contact press@chartbeat.com.

ABOUT CHARTBEAT
Chartbeat, the content intelligence platform for publishers, believes that today's content creators need mission-critical insights - in real time and across desktop, social and mobile platforms - to turn visitors into loyal audiences. That's why our software helps content creators understand what, within their content, keeps people engaged. Partnering with over 50,000 sites across 60+ countries, Chartbeat's software and front-line tools help the world's leading media companies harness the truth to measure and value the attention earned by their content.

Terri Walter - terri@chartbeat.com
Lauryn Bennett - lauryn@chartbeat.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Chartbeat via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum